- Home
- MPU vs TCRX Comparison
MPU vs TCRX Comparison
Compare MPU & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | TCRX |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 57.9M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPU | TCRX |
|---|---|---|
| Price | $0.88 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 363.6K | ★ 447.1K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.49 | $0.88 |
| 52 Week High | $4.44 | $2.57 |
Technical Indicators
Market Signals| Indicator | MPU | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 53.80 |
| Support Level | $0.78 | $0.90 |
| Resistance Level | $1.05 | $1.23 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.03 | 70.89 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.